180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and the companies that are developing those drugs. 180 Life Sciences is one of those companies. 180 Life Sciences Corp. was founded by four scientists that have a successful track record of developing new therapeutics that were acquired by larger pharmaceutical companies, sometimes for billions of dollars. The group of renowned scientist-entrepreneurs is focusing on replicating their past success with a pipeline of drug candidates in sequential stages of development that target untapped markets with significant potential.
To view the full press release, visit https://ibn.fm/kESoz
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. KBL Merger Corp. IV previously announced plans to merge with 180 Life Sciences and, in connection with the merger, consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on Aug. 28, 2020. Close of the business combination is expected in the fourth quarter of 2020. Following the merger, the new company will be listed on the Nasdaq Capital Market under ticker symbol “ATNF.” For more information, visit the company’s website at www.180LifeSciences.com.
KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap, with each share of 180 Life Sciences to be exchanged for one share of KBLM.
NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
